Earnings ·
Adaptive Biotechnologies reported second quarter 2026 revenue of $71.6 million, a 22% increase year-over-year, driven…
ADPTAdaptive Biotechnologies Corp
Adaptive Biotechnologies reported second quarter 2026 revenue of $71.6 million, a 22% increase year-over-year, driven by a 33% growth in its Minimal Residual Disease (MRD) segment to $66.2 million. The company completed a $345 million zero-coupon convertible senior notes offering and repaid the OrbiMed Purchase Agreement, resulting in a loss on extinguishment of $23.7 million. Consequently, net loss widened to $39.9 million from $25.6 million in the prior year period, though adjusted EBITDA improved to a loss of $0.7 million. Management raised full-year 2026 MRD revenue guidance to $268–$278 million and announced plans to separate its Immune Medicine business. Additionally, Co-founder and Chief Scientific Officer Dr. Harlan Robins transitioned to a strategic consultant role effective July 24, 2026. Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the adaptive immune system to develop clinical diagnostics and therapies for cancer and autoimmune disorders.